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Multiple myeloma is affected by multiple and heterogeneous
somatic mutations in adhesion- and receptor tyrosine kinase
signaling molecules
E Leich1,6, S Weibach1,6, H-U Klein2, T Grieb1, J Pischimarov1, T Stu¨hmer3, M Chatterjee3, T Steinbrunn3, C Langer4, M Eilers5, S Knop3,
H Einsele3, R Bargou3,7 and A Rosenwald1,7
Multiple myeloma (MM) is a largely incurable plasma cell malignancy with a poorly understood and heterogeneous clinical course.
To identify potential, functionally relevant somatic mutations in MM, we performed whole-exome sequencing of five primary MM,
corresponding germline DNA and six MM cell lines, and developed a bioinformatics strategy that also integrated published
mutational data of 38 MM patients. Our analysis confirms that identical, recurrent mutations of single genes are infrequent in MM,
but highlights that mutations cluster in important cellular pathways. Specifically, we show enrichment of mutations in adhesion
molecules of MM cells, emphasizing the important role for the interaction of the MM cells with their microenvironment. We
describe an increased rate of mutations in receptor tyrosine kinases (RTKs) and associated signaling effectors, for example, in EGFR,
ERBB3, KRAS and MAP2K2, pointing to a role of aberrant RTK signaling in the development or progression of MM. The diversity of
mutations affecting different nodes of a particular signaling network appears to be an intrinsic feature of individual MM samples,
and the elucidation of intra- as well as interindividual redundancy in mutations that affect survival pathways will help to better
tailor targeted therapeutic strategies to the specific needs of the MM patient.
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INTRODUCTION
Multiple myeloma (MM) is characterized by the expansion of
plasma cells in the bone marrow (BM), causing hematopoietic
insufficiency, osteolytic bone lesions and renal failure.1 The
introduction of the novel therapeutic agents thalidomide,
lenalidomide and bortezomib, in conjunction with autologous
stem cell transplantation protocols, has led to a considerable
improvement of overall survival times of MM patients.2 However,
the disease remains largely incurable and, moreover, shows a
remarkably heterogeneous clinical course, suggesting the
existence of different biologically defined subgroups. As a
prerequisite for novel targeted approaches, more insights into
the genetic and molecular pathogenesis of MM are therefore
warranted, which will lead to the identification of crucially
activated or inactivated survival pathways.
MM is thought to evolve through accumulation of a multitude of
genetic aberrations in a multi-step transformation process initiating
from a post-germinal center B-cell via the premalignant state of
monoclonal gammopathy of undetermined significance to overt
clinical disease. The occurrence of hyperdiploidy with chromosomal
trisomies or of genetic translocations involving the immunoglobulin
heavy chain locus and certain oncogenes represent rather early
pathogenetic events, whereas the progression to symptomatic MM
is frequently accompanied, if not facilitated by mutations of RAS,
TP53, genetic rearrangements or amplifications of MYC, mutations
affecting the nuclear factor-kB pathway and dysregulation of the
phosphoinositide-3-kinase/AKT pathway.2–4
Recent high-throughput genomic and whole-exome sequen-
cing efforts have set the stage for the description of the
genomic landscape of MM.5–7 Sequencing of 38 MM tumor
genomes/exomes identified novel, recurrent somatic mutations
that—despite their low frequency at the single gene level—
appear to cluster in important cellular pathways. For example, the
RNA-processing machinery and protein homeostasis mechanisms
are affected by mutations (DIS3, FAM46C), as are histone-
modifying enzymes (MLL, MLL2, MLL3). Frequent somatic muta-
tions of genes involved in the nuclear factor-kB pathway point to
a more potent role of this signaling cascade in MM than was
previously appreciated.5 BRAF mutations were detected in 4% of
MM cases,5 suggesting a potential therapeutic role for recently
developed BRAF inhibitors for such patients. Finally, sequencing
has also revealed differences in the mutational landscape between
t(4;14)- and t(11;14)-positive MM.7
Our own whole-exome sequencing efforts, including five
patient-derived (primary) MM samples, their matched normal
DNA and six MM cell lines, provide—in concert with previously
published data of 38 MM patients5—information on two
additional, functionally related groups of genes that show an
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enrichment of mutations in MM, namely adhesion- and receptor
tyrosine kinase (RTK)-associated molecules. The pivotal role of the
BM microenvironment in the maintenance and proliferation of the
tumor cell clone and in the response to therapy2,8–12 is well
established in MM. However, our findings suggest that MM cells
themselves are being selected for clones with increased numbers
of somatically mutated adhesion molecules that may modulate
their interaction with bystander cells of the BM microenvironment,
to promote anti-apoptotic or pro-proliferative properties, or to
decrease dependency during tumor progression. The finding of an
increased rate of mutations in genes involved in RTK function
underlines the importance of these signaling networks in the
pathogenesis of MM, and should stimulate efforts to interfere with
these signaling events therapeutically.
MATERIAL AND METHODS
MM specimens and cell lines
BM aspirates and corresponding peripheral blood mononuclear cells
(PBMCs) of five patients with MM were obtained after informed consent.
Two patients presented with an extramedullary involvement, one of whom
also had plasma cell leukemia and one MM showed anaplastic
morphology. Three patients were untreated at the time the biopsy was
taken, including the patient with anaplastic MM, whereas two patients had
received multiple prior lines of therapy. Tumor cells were isolated using
CD138 microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) as
previously described.13 Fluorescence in situ hybridizations for the detection
of losses in 13q14 and 17p13, gains in 1q21, 9q34 and chr11, and for the
translocations (4;14), 14;16) and (11;14) were performed according to
standard protocols (Supplementary Table S1).14,15 The human MM cell lines
JJN3, AMO1, U266, OPM2 and L363 were purchased from the German
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany), and MM.1S cells were purchased from LGC Biolabs (Wesel,
Germany). MM cells were cultured as previously described.13 The study was
approved by the Ethics Committee of the Medical Faculty, University of
Wu¨rzburg (reference number 18/09).
Whole-exome resequencing
Sample preparation of the primary MM and corresponding PBMC samples
and of the MM cell lines was performed using the Paired End DNA Sample
Preparation Kit from Illumina (Illumina, San Diego, CA, USA) according to the
standard protocol. Amplification and exome enrichment was performed
according to the V1 and V2 SeqCap EZ Exome Library SR user guides from
Nimblegen (Roche Diagnostics, Mannheim, Germany). Clonal cluster genera-
tion and 76bp paired-end sequencing was performed on the GAIIx (Illumina).
Microarray analysis
RNA and DNA were isolated from six MM cell lines, using the Allprep Kit, and
then hybridized to HG-U133 plus 2.0 arrays and SNP 6.0 arrays (Affymetrix,
Santa Clara, CA, USA) according to the manufacturer’s protocol.
Bioinformatic evaluation of sequencing data
File conversion and alignment. File conversion was performed using the
off-line base caller software (Illumina) and GERALD (Illumina), and
the alignment to the reference genome hg19 was performed using the
Burrows Wheeler Aligner. Furthermore, the sequences were processed
using the Picard tool and R/Bioconductor. For details see Supplementary
Material and Methods.
Single Nucleotide_Variant calling, filtering and biological interpretation.
Unpaired Single Nucleotide_Variant (SNV) calling was performed using
the Genome Analysis Toolkit pipeline as described,16 followed by the
SeattleSeq annotation and filtering steps (Figure 1). In addition, we
matched the readily filtered mutational data of 38 MM, published in the
supplements of Chapman et al.5 with the mutation data of our cases. This
increased the number of primary MM to 43 and helped us to efficiently
extract the tumor-relevant SNVs from our six cell lines (Figure 1).
Specifically, for our discovery approaches, we focused on genes that were
affected by a mutation in at least 1 of our 5 primary MM, or 1 of our 6 cell
lines, plus at least 1 of the 38 primary MM.5
The resulting gene lists (Figure 1) were then used to discover new
tumor-relevant pathways using the GSEA and String analysis.17,18
Information on protein domains was obtained using the graphical view
of the nucleotide database from NCBI and the String database. For details,
see Supplementary Material and Methods.
PCR and Sanger sequencing
For technical validation, PCR and Sanger sequencing were performed
using standard protocols. All primers (Supplementary Table S3) were
purchased from Integrated DNA Technologies (Leuven, Belgium).
RESULTS
Sequencing output and quality assessment
According to the sequencing chemistry and respective software
version used, we obtained 17–120 million reads per lane and
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Figure 1. SNV-filtering strategy. After alignment and SNV calling (see
Material and Methods), SNVs were filtered using different databases
and annotation tools. In a first step, SNVs were excluded that
appeared in the databases 1000 genomes or dbSNP, as they were
described to occur in healthy individuals. Next, SNVs were excluded,
which did not lead to an amino acid exchange (synonymous
mutations) and which were benign according to the predictor tool
Polyphen 1, using the SeattleSeq annotation tool. Of note, this
annotation refers to all transcripts of a gene, which leads to a higher
amount of total SNVs. In detail, it might occur that the SNV is located
to the same position, but might affect different transcripts. Thus, the
amount of detected SNVs after annotation does not equal the amount
of SNVs before SeattleSeq annotation. Moreover, SNVs were excluded
that occurred in the corresponding blood samples, as we were
interested in tumor-related SNVs. In addition, we decided to focus on
genes that were affected in at least one of the primary MM sample. To
extract the tumor-relevant SNVs efficiently from the 6 cell lines, we
integrated the previously published mutation data of 38 MM.5 This
allowed us to exclude SNVs that affected genes in only a cell line but
not in a primary sample (including Chapman et al.5). Finally, we
applied three functional predictors to increase the possibility that the
detected amino acid exchange leads to a functional change.
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56–192 million reads per sample, performing a 36- or 76-bp paired
end run on a GAIIx. Of those reads, approximately 90% could be
mapped to the reference genome. On average, 10% of those reads
were not unique or mapped to more than one position. Mapping
of those reads to the target region revealed 50–80% of uniquely
mapped unique reads ‘on target,’ dependent on the enrichment
kit and the read length used. With the SBS v5 chemistry (Illumina)
and the SCS 2.9 software (Illumina), we obtained an average
coverage ‘on target’ of B100 per lane. Uniformity at 1
coverage was, on average, 97%. One sample pair showed a worse
uniformity for unknown reasons and was, thus, not included in
this calculation. The transition/transversion ratios were around 3.0
in all samples, indicating a low rate of false-positive calls and no
significant technical bias. All technical parameters and a more
detailed description of this Results section can be found in
Supplementary Table S2 and Supplementary Results.
SNV filtering and validation
To detect somatic mutations that might be relevant for MM
pathogenesis, we developed a bioinformatics pipeline. This
included the extraction of tumor-associated SNVs using the
databases dbSNP and 1000 genomes, and the corresponding
normal sample of each primary MM, SeattleSeq annotation to
extract the non-synonymous SNVs, as well as the application of
functional predictors (Polyphen, phastCons, GERP) to determine
SNVs at conservative sites or SNVs that may lead to structural
changes. By this strategy, 55 363 raw SNVs that were called in a
total of 16 samples (6 MM cell lines and 5 primary MM, plus
corresponding PBMC samples) were narrowed down to 330
putative cancer-relevant SNVs (Figure 1, Supplementary Table S4
and Table S5). Moreover, we integrated published mutation data
of 38 primary MM5 to efficiently extract tumor-relevant SNVs
from the 6 MM cell lines. Interestingly, 480/1429 of the mutated
genes that were published by Chapman et al.,5 were also
mutated in our data set. Thus, for our discovery approach we were
able to focus on those genes that were mutated in at least 1
sample of our data set (including cell lines), but also in at least 1
primary MM (5 own and 38 published) (Figure 1). Validations by
Sanger sequencing were performed randomly after SeattleSeq
annotation (4130 SNVs) at various steps of the analysis. In
total, 199 of 213 SNVs (94.3%) could be confirmed (primers listed
in Supplementary Table S3), indicating only a very low technical
bias as already evidenced by the good transition/transversion
ratio. For more details, see legend of Figure 1 and Supplementary
Results.
MM is characterized by a low frequency of recurrent gene
mutations
In line with the previous report,5 our results confirm that recurrent
gene mutations are rare in MM. Combining both data sets, only 8
genes (KRAS, FAM46C, WHSC1, DIS3, LRP1B, PKHD1, NRAS, ALOX12B)
were affected in at least 4 out of 43 primary MM and at least 1 MM
cell line, and passed the thresholds for at least 2 functional
predictors (Supplementary Table S6). Of note, all mutations were
validated by Sanger sequencing in the cell lines and the primary
MM samples.
Higher mutational load in MM with anaplastic morphology
After SeattleSeq annotation and before the exclusion of SNVs
detected in the corresponding blood (Figure 1), MM cell lines
showed an overall higher mutational load than the primary MM as
expected (Figure 2). Only one primary MM (Patient 1, Figure 2)
showed a mutational load equivalent to the one observed in MM
cell lines. Interestingly, this MM, studied at primary diagnosis,
showed an anaplastic morphology. Of note, the number of total
SNVs per primary MM was dramatically reduced (up to 16 ) after
exclusion of the SNVs, which also occurred in the corresponding
PBMC sample, emphasizing the advantage of the inclusion of
matched normal DNA for an unbiased SNV-filtering approach and
supporting our strategy to focus on mutations that occurred in at
least one primary MM.
The mutational profile of MM is enriched for genes associated with
growth factor receptor and adhesion molecule signaling
Pathway annotation of the 79 genes (137 SNVs, Supplementary Table
S7) affected in at least 1 of our 5 primary MM or in 1 of our 5 primary
MM and in any of the 6 cell lines revealed an enrichment of 9 growth
factor receptor signaling pathways and 1 adhesion pathway among
the top 20 gene sets (Table 1), and 15 growth factor receptor
signaling pathways and 1 adhesion pathway among the 50 most
significant gene sets (Supplementary Table S8). Moreover, annotation
of the 193 genes (330 SNVs, Supplementary Table S5) that are
affected in at least 1 of our 5 primary MM or in 1 MM cell line, plus at
least 1 of the 38 primary MM of the Chapman data set, revealed an
enrichment of 14 pathways related to specific cancers (for example,
liver, melanoma) or cancer in general, and 3 adhesion pathways
among the first 20 gene sets (Supplementary Table S9A). Among the
top 50 gene sets, we detected 4 adhesion-associated pathways and 4
growth factor receptor signaling pathways (Supplementary Table
S9B). In an independent validation approach, pathway analysis was
performed on genes that were mutated in the published 38 primary
MM cases (1429), revealing an enrichment of 2 adhesion-associated
pathways among the 20 most significant gene sets, and 4 adhesion-
associated pathways among the top 50 most significant gene sets
(Supplementary Table S10). Moreover, an enrichment of two gene
sets associated with histone modification was observed, which
confirms the findings of Chapman et al.5 that this pathway might
have an important role in MM pathogenesis.
Mutations in RTKs and their downstream effectors
Given the importance of tyrosine kinase signaling in the
pathogenesis of MM and its therapeutic relevance in other
cancers, we screened our data set (after exclusion of SNVs
detected in the corresponding PBMC samples, Figure 1) for
Figure 2. Mutation load of the six MM cell lines and the five primary
MM samples. MM cell lines showed an overall higher mutation load,
with the exception of Patient 1. The bars in dark gray reflect the
mutation load after SeattleSeq annotation and before the exclusion
of SNVs detected in the corresponding blood (see Figure 1).
The bars in light gray reflect the mutation load of the primary
sample after the exclusion of SNVs that occurred in the correspond-
ing blood.
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mutations in 91 known RTKs (Supplementary Table S11 A) and
discovered that 14 out of 91 RTKs (B15%) were mutated in our
data set. Compared with the reported average mutation rate of 35
non-synonymous SNVs in MM,5 which is similar to our results in
primary MM (Patient 1–5, bars in light gray, Figure 2), this
represents a high enrichment. Specifically, we found somatic
mutations in some well-known RTKs, such as IGF1R, EGFR, ERBB3,
NTRK1 and NTRK2, as well as in several potential downstream
effectors, such as KRAS, BRAF, MAP2K2, AKAP1, IKBKE, STAM2 and
GRK. All of these mutations occurred in at least one primary MM
and all were designated as ‘damaging’ (mutations occur at
conservative sites or lead to structural changes) by three different
functional predictors (Figure 3a and Table 2). Mutations in NTRK1,
NTRK2, AKAP1, IKBKE, STAM2, GRK2/ADRBK1 and MAP2K2 have not
previously been reported in MM. All but one mutation labeled in
Figure 3a were validated by Sanger sequencing in our data set.
Mutations in adhesion molecules and their downstream effectors
The finding that the pathway annotation of genes mutated in MM
revealed the biological feature of ‘adhesion’ caught our interest, as
the microenvironment is known to have an important role in MM
pathogenesis. Therefore, we screened 653 known adhesion
molecules (Supplementary Table S11 B) and found that 201 of
those (B31%) were mutated in our data set. These mutations
affected integrins (for example, ITGB1, ITGB5, ITGA7 and TGFBR2),
several cadherins (for example, CDH9, CDH11, CDH18 and CDH23)
and protocadherins (for example, PCDH9, PCDHGA3, PCDH10 and
PCDH20), as well as ICAM and NCAM2, extracellular matrix
molecules (for example, COL10A1 and LAMB2), proteoglycans (for
example, VCAN and BCAN), metalloproteases (for example,
ADAM29 and ADAMTS1), as well as different ephrin receptors (for
example, EPHB2 and EPHA2) and several downstream effectors
(partially shown in Figure 3b and Table 2). Of note, there was no
prevalence of mutations affecting adhesion molecules in the two
MM patients with extramedullary involvement. Mutations marked
in Figure 3 and also present in cell line(s) are detailed in
Supplementary Table S12. All but one mutation labeled in
Figure 3b were validated by Sanger sequencing.
Approximately 50% of MMs are affected by more than one
mutation in the same signaling network
We noticed that some MM cell lines carried multiple mutations
within the same signaling network. For example, in the cell line
AMO1, mutations potentially affecting the mitogen-activated
protein kinase pathway were found for EGFR, ERBB3, KRAS
(A146T) and MAP2K2. This prompted us to investigate this
surprising finding in MM cell lines and primary MM in more detail.
All 6 MM cell lines and all primary MM samples, as well as
almost all 38 primary MM (36/38 of MM reported in Chapman
et al.5) carried mutations in genes that encode parts of the same
signaling network containing adhesion molecules, RTKs and their
downstream effectors (Table 2, Supplementary Table S13 and 14).
Moreover, all 6 MM cell lines and approximately 50% of primary
MM (including Chapman et al.5) showed mutations in more than 1
gene of the same signaling network, and approximately 30%
showed more than 2 mutations within this network. Of note, the
second largest number of mutations (n¼ 16) within this network,
affecting the adhesion molecules SDK1, LRFN5, THBS1, SLAMF1,
VCAN, ALOX12B, NCAM2 and TGFBR2, the RTK EPHB2 and EPHA8,
and the effector molecules HK3, STAM2, IKBKE, ADRBK1, AKAP1
and MAP2K2, was identified in 1 primary MM showing anaplastic
features (Table 2). Thus, this biological feature does not only
seem to be a culture artefact of established MM cell lines,
but is probably also a genuine trait of malignant plasma cell
clones in vivo.
Correlation of somatic mutations with copy number, gene
expression and copy neutral loss of heterozygosity
In the six MM cell lines, selected mutations in RTKs and adhesion
molecules were correlated with mRNA expression, chromosomal
copy number changes and copy neutral loss of heterozygosity
(Tables 3a and b, for mutation details see Supplementary Table
S14). The EGFR mutation in MM.1S showed a weak, positive
correlation with gene expression (Table 3). Moreover, IGF1R, NTRK1
and ERBB3 mutations were accompanied by increased copy
numbers. Although we observed only a weak correlation of
somatic mutations and gene expression for RTKs, we noticed a
remarkable correlation for mutations in adhesion molecules with
Table 1. GSEA pathway annotation
Gene set name Genes in gene set Genes in overlap P-value
REACTOME SIGNALING BY EGFR 48 4 1.59E-05
ST_MYOCYTE_AD_PATHWAY 23 3 5.09E-05
KEGG_LONG_TERM_DEPRESSION 70 4 7.12E-05
KEGG_LONG_TERM_POTENTATION 70 4 7.12E-05
VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1 36 3 1.99E-04
ST_B_CELL_ANTIGEN_RECEPTOR 39 3 2.53E-04
KEGG_BLADDER_CANCER 42 3 3.16E-04
BENPORATH_SUZ12_TARGETS 1037 11 3.82E-04
NAKAMURA_METASTASIS 47 3 4.42E-04
VERRECCHIA_RESPONSE_TO_TGFB1_C4 11 2 5.30E-04
KEGG_ENDOMETRIAL_CANCER 52 3 5.95E-04
REACTOME_SHC_MEDIATED_SIGNALING 12 2 6.34E-04
KEGG_NON_SMALL_CELL_LUNG_CANCER 54 3 6.65E-04
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 126 4 6.81E-04
KEGG_AXON_GUIDANCE 129 4 7.44E-04
REACTOME_GRB2_EVENTS_IN_EGFR_SIGNALING 13 2 7.48E-04
REACTOME_SOS_MEDIATED_SIGNALING 13 2 7.48E-04
KEGG_TIGHT_JUNCTION 134 4 8.57E-04
AMIT_EGF_RESPONSE_20_MCF10A 14 2 8.71E-04
REACTOME_SHC_RELATED_EVENTS 14 2 8.71E-04
Abbreviation: GSEA, gene set enrichment analysis. Twenty most significant gene sets; 79 genes, mutated in at least 1 of the 5 primary MM (Figure 1) were
annotated to pathways, using the c2 collection of the GSEA annotation database. Red label: growth factor receptor signaling pathways, yellow label: adhesion-
associated pathway. For the top 50 gene sets see Supplementary Table S8.
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gene expression (Table 3). Specifically, in the presence of the
respective mutation, we observed a fourfold upregulation of TNC,
a fourfold downregulation of LAMA5 and a ninefold down-
regulation of both LAMB2 and RELN. Moreover, LAMB2 was
affected by cn-loss of heterozygosity in MM.1S, pointing to a
possible suppressor function. From four primary MM samples,
cytogenetic information was available (Supplementary Table S1).
Of note, the MM sample with p53 deficiency carried the least
number of mutations in adhesion- and RTK-associated molecules,
suggesting a dominant pathogenetic event for the p53 alteration
that might make additional mutations in the adhesion/RTK
network dispensable.
Tyrosine kinase catalytic domains of RTKs are frequently affected
by somatic mutations in MM
To gain more information on the potential biological impact of the
non-synonymous mutations in RTKs listed in Table 3, we searched
Figure 3. (a) RTK signaling and (b) adhesion molecule signaling. Asterisks indicate a mutation. Asterisks in red (bold): mutated in at least one
primary MM (including Chapman et al.5) and ‘damaging’ according to three functional predictors. Asterisks in red: mutated in 1 of the 43
primary MM (including Chapman et al.5). Asterisks in black (bold): mutated in a cell line and ‘damaging’ according to three functional
predictors. Asterisks in black: mutated in at least one cell line. All mutations were confirmed by Sanger sequencing in our samples, except for
MMp15. Moreover, sequence information of GRK/ADBRK1 was not evaluable. Please note that not all members of a family were validated (for
details see Supplementary Table S12).
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for the affected domains using the Nucleotide database from NCBI
and the String database. Of note, three out of five RTKs (NTRK2,
IGF1R and EGFR) were affected by mutations in the tyrosine kinase
domain in at least one of the samples investigated, and the
remaining mutations mostly affected the furin-like domains or
the region between two furin-like domains, close to the ligand-
binding domain. For example, the somatic point mutations in
NTRK2 affected the tyrosine kinase catalytic domain in one primary
MM of our discovery set (Supplementary Figure S1); IGF1R showed
a somatic point mutation in L363 in the tyrosine kinase catalytic
domain, and the somatic point mutations in EGFR that were
detected in MM.1S and in a primary MM5 also appeared to target
the tyrosine kinase catalytic domain. For more details see
Supplementary Results.
Table 2. Mutation profile of six cell lines and five primary MM samples with respect to adhesion and RTK signaling
Gene AMO1 U266 OPM2 MM1S JJN3 L363 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
MMP15 x(homoz.) x x
MUC4 xx (o2) x
COL10A1 x x
SDK1 x x
LRFN5 x x x
THBS1 x x
SLAMF1 x
COL6A3 xx x
VCAN x
THSD7A x
ALOX12B x (o2) x
HSD17B1 x
NCAM2 x
ADAM29 x x
ADAMTS1 x
ADAMTSL1 x(homoz.)
BCAN x x
COL17A1 x
COL7A1 x
DCHS1 x x
DCHS2 x
ITGA10 x x
ODZ1 x
SIGLEC1 x
WHSC1 x
LAMB2 x
PCDHGA7 x xx x
ADAMTS19 x (o2) x
ADAMTS9 x
CAMTA1 x
ADAMTS2 x (o2) x
COL12A1 x
COL16A1 x
HS6ST3 x x
LAMA5 x x
NRXN1 x
ODZ4 x
PCDH10 x
ADAMTS18 x
CDH11 x
CELSR2 x
GPC6 x x
ITGB1 x
LAMB1 x
PCDH15 x(homoz.)
PCDH17 x
PCDH20 x
RELN xx
SPOCK1 x
TLN2 x
TNC x x (o2)
TGFBR2 x
CHIA x(homoz.)
NTRK1 x x
EPHB2 x
EPHA8 x x x
NTRK2 x xx
EGFR x x
ERBB3 x x
IGF1R x
TTN x (o2)
HK3 x
STAM2 x
IKBKE x
ADRBK1 x
AKAP1 x
TYK2 x
KRAS x x x
NRAS x
BRAF x
MAP2K2 x x
Abbreviations: MM, multiple myeloma; RTK, receptor tyrosine kinase; x, mutated; xx, mutated twice in the same sample; homoz., homozygous Adhesion
molecules, RTKs and some downstream molecules are listed that were mutated in at least 1 of the5 primary MM or in at least 1 cell line, plus at least 1 of the 38
published primary MM.5 All mutations mentioned (x, xx, homoz.) were damaging in at least two functional predictors, if not otherwise specified (o2¼ less
than 2 predictors). Genes that belonged to the same signaling network according to the STRING database or manual literature search were highlighted in
bold and italics (bold: medium confidence; italics: low confidence). The mutation details for the 38 primary MM5 are shown in Supplementary Table S12.
Screening for mutations in multiple myeloma
E Leich et al
6
Blood Cancer Journal & 2013 Macmillan Publishers Limited
DISCUSSION
With the use of novel drugs, such as thalidomide, lenalidomide and
bortezomib, and risk-adapted strategies, including autologous stem
cell transplantation in eligible patients, 10-year overall survival rates
in the small subset of MM patients younger than 60 years have
reached up to 30%.2,3,19 Patients who carry MM clones with hyper-
diploidy or a t(11;14) were shown to have a relatively better outcome
compared with those whose tumors harbor a t(4;14), t(14;16) or del
17p.20 Interestingly, MM patients carrying the t(4;14) translocation
that often leads to deregulation of FGFR3 seem to benefit from the
inclusion of bortezomib into their first-line treatment21 in that the
adverse prognosis may be overcome. This suggests future concepts
in which the detection of molecular alterations may ultimately lead
to refinement of therapeutic approaches. Nevertheless, MM currently
remains largely incurable and efforts are underway to develop more
individualized, molecular therapies that target critical growth and
survival pathways in the tumor cells.
Novel sequencing technologies nowadays allow for the
identification of somatically mutated genes in malignant tumors
on a global scale. Initial genome sequencing of MM5 and
published literature suggest that recurrent genetic translocations
(t(11;14), t(4;14), t(14;16)) or oncogene mutations, for example, in
KRAS or NRAS, with frequencies of at best 15–20%.3 Novel
mutations are detected at even lower frequencies. BRAF, for
example, is mutated in only 4% of all samples,5 in sharp contrast
to the scenario in hairy cell leukemia that harbors BRAF mutations
in most, if not all tumors.22 Thus, it appears unlikely that the
development of a targeted therapy against a single molecule will
prove to be a successful strategy in MM. Rather, there has been a
recent focus in clinical phase I/II trials to test the hypothesis
whether the modulation of molecular pathways, for example, by
inhibiting mitogen-activated protein kinase or AKT, or by using
epigenetic agents, could represent a promising way forward.23,24
Such an approach is supported by a recent sequencing analysis of
38 MM tumor genomes/exomes that showed clustering of somatic
mutations in important cellular pathways, including the RNA-
processing machinery, histone-modifying enzymes and genes
involved in nuclear factor-kB signaling.5
Our discovery and validation approach, integrating altogether
43 primary MM samples (including published MM samples) and 6
MM cell lines, provides evidence that the neoplastic cells in MM
are affected by multiple and heterogeneous somatic mutations in
adhesion- and RTK-associated signaling molecules, which is a
hitherto undescribed finding. Notably, 147 out of 201 mutated
adhesion molecules were newly detected in our analysis, including
the integrins ITGA6, ITGA7 and ITGB5, the cadherins CDH23, CDH18
and CDH9, and the protocadherin clusters (for example, PCDH9
and PCDHGA3) among others. Twenty mutations in adhesion
molecules were found to be affected in at least 1 of the 43 primary
MM samples and 1 cell line, were ‘damaging’ by at least 2
functional predictors and were validated by Sanger sequencing.
Available gene expression and copy number data in six
investigated MM cell lines allowed us to correlate the presence
of specific mutations in adhesion-associated molecules with
accompanying alterations on the mRNA expression and genomic
copy number level. From this analysis, it remains unclear whether
mutations in adhesion molecules might increase or decrease their
function, that is, whether they might act as oncogenes or as tumor
suppressors.
However, the frequent occurrence of somatic mutations in
adhesion molecules in primary MM emphasizes their presumably
important biological role for the interaction of the neoplastic
plasma cells with their BM microenvironment. For example, the
interaction between MM cells and BM stromal cells was shown to
provide adhesion-mediated drug resistance.8,25,26 In addition, this
interaction may lead to the activation of signal transduction
pathways that promote cell cycle progression and cell survival via
expression of growth factors such as insulin-like growth factor and
vascular endothelial growth factor, as well as chemokines and
cytokines.8 Our results support the notion that MM cells are being
selected for clones with increased numbers of mutated adhesion
molecules during tumor evolution. As a consequence, therapeutic
efforts to more effectively target the interaction between MM cells
and their surrounding stroma appear reasonable, a strategy
that is currently tested in chronic lymphocytic leukemia, in which
the stromal cell-derived factor-1/C-X-C chemokine receptor
type 4 axis in BM and lymph node infiltrates is targeted by the
C-X-C chemokine receptor type 4antagonists, such as plerixafor
and T140.27
Another important finding of our study is the enrichment of
somatic mutations in RTKs in MM cells. The well-known RTKs EGFR,
IGF1R, ERBB3, NTRK1 and NTRK2 were affected in at least 1 of the
43 primary MM samples and in at least 1 MM cell line, and
Table 3. Correlation of selected mutations in RTKs and adhesion
molecules with gene expression, CN changes and copy neutral LOH
Gene GE CN LOH CL Predictors
(A)
IGF1R — þ L363 3
NTRK2 — — L363 3
NTRK1 — þ MM1S 2
EGFR — — AMO1 2
EGFR m — MM1S 2
ERBB3 — þ AMO1 3
ERBB3 — — L363 3
(B)
SDK1 — þ JJN3 3
LRFN5 — — X MM1S 3
LRFN5 — — U266 3
DCHS2 — þ OPM2 3
DCHS2 — — MM1S 3
SIGLEC1 — þ U266 2
SIGLEC1 — — MM1S 3
PCDHGA7 — — JJN3 2
PCDH10 — — AMO1 3
THBS1 — — AMO1 2
BCAN — þ þ X AMO1 3
BCAN k þ þ OPM2 3
LAMB2 kkk — X MM1S 3
CAMTA1 — — OPM2 3
ADAMTS2 — — OPM2 3
ADAMTS2 — — AMO1 2
LAMA5 kk þ OPM2 2
LAMA5 — — MM1S 3
TNC mm — AMO1 3
ADAMTS19 k — U266 3
COL12A1 — — L363 3
CDH11 — — L363 3
CELSR2 — þ JJN3 3
ITGB1 kk — X U266 3
PCDH20 m þ AMO1 3
RELN kkk þ U266 3
Abbreviations: CL, cell line; CN, copy number; GE, gene expression; LOH,
loss of heterozygosity; MM, multiple myeloma; RTK, receptor tyrosine
kinase. One arrow represents a twofold up- or downregulation, one and a
half arrows a threefold up- or downregulation, two arrows a fourfold up- or
downregulation, and three arrows a ninefold up- or downregulation in
mRNA expression compared with the median mRNA expression of all six
cell lines; ± represents a simple copy number gain (three copies) and
þ þ represents four copies of that gene. Copy neutral LOH or LOH that
was accompanied by a chromosomal gain is depicted by x. aRTKs and
adhesion molecules that were mutated in at least 1 of the 43 primary MM
(including Chapman et al.5) and 1 cell line, that were ‘damaging’ by at least
2 functional predictors and that were validated by Sanger sequencing.
These conditions apply to all genes of Table A and B.
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mutations in these genes were predicted to be ‘damaging’
according to at least 2 functional predictors. This finding is of
interest for two reasons. First, RTKs likely have a role in the
pathogenesis of MM, as evidenced by the presence of FGFR3
translocations in a considerable subset of MM,2 and signaling
cascades downstream of RTKs that involve the aberrant activation
or deregulation of the RAS/mitogen-activated protein kinase and
phosphoinositide-3-kinase/AKT pathways are frequently altered
in MM.10,28,29 Second, these receptors may represent interesting
targets for novel therapeutic approaches reinforcing initial
concepts in MM to develop small-molecule inhibitors that block
anti-apoptotic or pro-proliferative effects of RTK activation. RTK
inhibition is already a widely used strategy for treating various
types of solid cancers, including epidermal growth factor receptor
inhibitors (erlotinib, gefitinib) in non-small cell lung cancer or the
monoclonal antibody trastuzumab and the small-molecule
inhibitor lapatinib in patients with ERBB2/HER2-neu positive
breast and gastric cancer, respectively.30–32 More recently,
insulin-like growth factor-1 receptor inhibitors have been under
investigation in clinical trials of non-small cell lung cancer, Ewing
sarcoma and prostate cancer.33–37 Given the increased frequency
of RTK mutations in MM, therapeutic intervention using RTK
inhibitors could prove useful in subsets of MM patients.
Our data, in line with published results,5 suggest that the
pathogenesis and progression of MM is accompanied by the
development of multiple and heterogeneous somatic mutations in
various important cellular signaling cascades (RNA-processing
machinery, histone-modifying enzymes, nuclear factor-kB system,
adhesion- and RTK-associated molecules), leading to a profound
‘interindividual pathway redundancy’. For example, all 6 MM cell
lines and approximately 95% of 43 primary MM samples carried
mutations in at least 1 adhesion molecule, RTK or RTK
downstream-signaling effector that all cluster within the same
signaling network, indicating that pathways belonging to this
network are of importance in MM pathogenesis. Approximately
50% of primary MM were affected by mutations in more than one
gene of this network, and almost one third of primary MM samples
carried multiple mutations (42) in this signaling network,
suggesting an ‘intra-individual pathway redundancy’. Of note, 1
MM with anaplastic morphology carried 16 mutations (including,
for example, ALOX12B, NCAM2, EPHB2 and MAP2K2). This observed
pathway redundancy’ underlines the necessity of comprehensive
genetic approaches to make informed decisions on how to
employ future targeted molecular therapies most effectively for
the benefit of individual MM patients.
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